Science重磅：暴饮暴食并非意志薄弱！华人科研团队揭秘大脑如何控制食欲，肥胖治疗迎来新突破

Core Viewpoint - The article highlights the alarming rise in global obesity rates and emphasizes the need for urgent measures to combat this crisis, particularly through innovative treatments such as GLP-1 weight loss drugs and new research findings related to appetite regulation [6][7][12]. Group 1: Global Obesity Trends - As of 2021, 2.11 billion adults and 493 million children and adolescents were affected by overweight or obesity, with projections indicating that by 2050, 60% of adults (approximately 3.8 billion) and 31% of children and adolescents (around 750 million) may face similar risks [6]. Group 2: Advances in Obesity Treatment - The emergence of GLP-1 class weight loss drugs, such as semaglutide and tirzepatide, represents a significant breakthrough in obesity prevention and treatment [7]. - Recent research has identified a previously unknown signaling pathway in the brain's neurons that plays a crucial role in appetite regulation, opening new avenues for obesity treatment [7][12]. Group 3: Research Findings on GPR45 - A study published in Science revealed that the G protein-coupled receptor (GPCR) family member GPR45 is essential in regulating eating behavior by transporting key signaling molecules to the primary cilia of neurons [7][10]. - GPR45's absence leads to obesity due to increased food intake, as it disrupts the brain's ability to receive satiety signals [10][12]. - The study found that GPR45's role is not merely in signal transduction but in the precise localization of Gαs to cilia, which is critical for appetite control [12]. Group 4: Implications for Drug Development - Given the high homology of human GPR45 with its mouse counterpart and the prevalence of GPCRs as drug targets, this discovery provides a valuable target for the development of new anti-obesity medications [12].